- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00989391
A Study In Healthy People To Investigate The Safety, Toleration And Time Course Of Blood Concentrations Of Multiple Doses Of PF-03654764, Given By Mouth
15. prosince 2009 aktualizováno: Pfizer
A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Oral Doses Of PF-03654764 In Healthy Subjects
The purpose of this study in heathy people is to investigate the safety, toleration and time course of PF-03654764 in the blood, following multiple doses given once or twice daily by mouth for 10 days.
Přehled studie
Postavení
Dokončeno
Podmínky
Intervence / Léčba
Typ studie
Intervenční
Zápis (Aktuální)
36
Fáze
- Fáze 1
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
-
Singapore, Singapur, 188770
- Pfizer Investigational Site
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
21 let až 55 let (Dospělý)
Přijímá zdravé dobrovolníky
Ne
Pohlaví způsobilá ke studiu
Všechno
Popis
Inclusion Criteria:
- Healthy subjects. (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- A positive urine drug screen.
- Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Základní věda
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Cohort 1
Subjects will be assigned to receive either PF-03654764 or placebo.
|
5mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
oral twice daily on Days 1-9 and once on Day 10.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
|
|
Experimentální: Cohort 2
Subjects will be assigned to receive either PF-03654764 or placebo.
|
5mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
oral twice daily on Days 1-9 and once on Day 10.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
|
|
Experimentální: Cohort 3
Subjects will be assigned to receive either PF-03654764 or placebo.
|
5mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally once daily for 10 days.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
oral twice daily on Days 1-9 and once on Day 10.
After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated.
If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped.
The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK.
Nominal administered doses will not exceed 24 mg per day.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
safety & toleration: Adverse events, vital signs, 12 lead ECG, blood and urine safety tests, suicidality assessment using the Suicidality Tracking Scale (STS) and physical examination.
Časové okno: 10 days
|
10 days
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Plasma pharmacokinetics: Cmax, Tmax, AUCtau, t½, AUCtau (Day 10)/AUCtau (Day 1), CL/F
Časové okno: 10 days
|
10 days
|
|
Urine pharmacokinetics: Ae24 & Ae24% (for once daily doses) or Ae12 & Ae12% (for twice daily dose) on Day 10, CLR
Časové okno: 10 days
|
10 days
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia
1. října 2009
Primární dokončení (Aktuální)
1. prosince 2009
Dokončení studie (Aktuální)
1. prosince 2009
Termíny zápisu do studia
První předloženo
2. října 2009
První předloženo, které splnilo kritéria kontroly kvality
2. října 2009
První zveřejněno (Odhad)
5. října 2009
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
16. prosince 2009
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
15. prosince 2009
Naposledy ověřeno
1. prosince 2009
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- B0711002
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Ne
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ne
produkt vyrobený a vyvážený z USA
Ne
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .